{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T06:52:29Z","timestamp":1792306349075,"version":"4.4.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.vaccine.2025.127264","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T20:36:02Z","timestamp":1748032562000},"page":"127264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Economic evaluation of PCV21 in PCV-na\u00efve adults aged 50\u201364\u00a0years in the United States"],"prefix":"10.1016","volume":"59","author":[{"given":"Zinan","family":"Yi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwame","family":"Owusu-Edusei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elamin H.","family":"Elbasha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.vaccine.2025.127264_bb0005","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00540-21","article-title":"Structural, genetic, and serological elucidation of serogroup 24 serotypes: discovery of a new serotype, 24C, with a variable capsule structure","volume":"59","author":"Ganaie","year":"2021","journal-title":"J Clin Microbiol"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127264_bb0010","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00937-20","article-title":"A new pneumococcal capsule type, 10D, is the 100th serotype and has a large fragment from an oral streptococcus","volume":"11","author":"Ganaie","year":"2020","journal-title":"Mbio"},{"issue":"9","key":"10.1016\/j.vaccine.2025.127264_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22094580","article-title":"Carbon source-dependent changes of the structure of Streptococcus pneumoniae capsular polysaccharide with serotype 6F","volume":"22","author":"Werren","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127264_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7203a1","article-title":"Pneumococcal vaccine for adults aged >\/=19 years: recommendations of the advisory committee on immunization practices, United States, 2023","volume":"72","author":"Kobayashi","year":"2023","journal-title":"MMWR Recomm Rep"},{"issue":"6","key":"10.1016\/j.vaccine.2025.127264_bb0025","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41579-018-0001-8","article-title":"Streptococcus pneumoniae: transmission, colonization and invasion","volume":"16","author":"Weiser","year":"2018","journal-title":"Nat Rev Microbiol"},{"issue":"11","key":"10.1016\/j.vaccine.2025.127264_bb0030","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S1473-3099(18)30310-4","volume":"18","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"36","key":"10.1016\/j.vaccine.2025.127264_bb0040","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.1016\/j.vaccine.2009.05.061","article-title":"Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: a systematic review of conclusions and assumptions","volume":"27","author":"Ogilvie","year":"2009","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127264_bb0045","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMra052116","article-title":"Current concepts: community-acquired bacterial meningitis in adults","volume":"354","author":"van de Beek","year":"2006","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127264_bb0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060273","article-title":"Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques","volume":"8","author":"Said","year":"2013","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.vaccine.2025.127264_bb0055","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1093\/cid\/ciy800","article-title":"Decline in pneumococcal disease attenuated in older adults and those with comorbidities following universal childhood PCV13 immunization","volume":"68","author":"Pelton","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2025.127264_bb0060","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1136\/thoraxjnl-2015-206780","article-title":"Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and\/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease","volume":"70","author":"Torres","year":"2015","journal-title":"Thorax"},{"key":"10.1016\/j.vaccine.2025.127264_bb0075","series-title":"Active bacterial Core surveillance: Atlanta, GA","author":"Centers for Disease Control and Prevention, 1998\u20132021 Serotype Data for Invasive Pneumococcal Disease Cases by Age Group from Active Bacterial Core surveillance","year":"2023"},{"key":"10.1016\/j.vaccine.2025.127264_bb0080","article-title":"Current epidemiology of pneumococcal disease among adults, United States: presentation to the ACIP, February 29, 2024","author":"Gierke","year":"2024","journal-title":"Ctr Dis Control Prev"},{"key":"10.1016\/j.vaccine.2025.127264_bb0085","series-title":"Lifetime health and economic burden of invasive pneumococcal diseases attributable to V116 serotypes among adults in the United States","author":"Yi","year":"2024"},{"key":"10.1016\/j.vaccine.2025.127264_bb0090","series-title":"Rahway, New Jersey, USA, U.S. FDA Approves CAPVAXIVE\u2122 (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults","author":"Merck & Co., Inc.","year":"2024"},{"issue":"36","key":"10.1016\/j.vaccine.2025.127264_bb0095","doi-asserted-by":"crossref","first-page":"793","DOI":"10.15585\/mmwr.mm7336a3","article-title":"Use of 21-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Recommendations of the advisory committee on immunization practices - United States","volume":"73","author":"Kobayashi","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep, 2024"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127264_bb0100","doi-asserted-by":"crossref","first-page":"109","DOI":"10.15585\/mmwr.mm7104a1","article-title":"Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among US adults: updated recommendations of the advisory committee on immunization practices-United States, 2022","volume":"71","author":"Kobayashi","year":"2022","journal-title":"Mmwr-Morbidity and Mortality Weekly Report"},{"key":"10.1016\/j.vaccine.2025.127264_bb0105","unstructured":"Kobayashi M. Evidence to recommendation framework: risk-based use of 15-valent and 20-valent pneumococcal conjugate vaccines in adults: presented to the ACIP Meeting on September 29, 2021. Ctr Dis Control Prev 2021. Available from: https:\/\/stacks.cdc.gov\/view\/cdc\/110718."},{"key":"10.1016\/j.vaccine.2025.127264_bb0110","unstructured":"Kobayashi M. Summary of work group interpretation of EtR and policy options: PCV use in adults: Presented to the ACIP Meeging on June 27, 2024. Ctr Dis Control Prev 2024. Available from: https:\/\/stacks.cdc.gov\/view\/cdc\/157880."},{"issue":"1","key":"10.1016\/j.vaccine.2025.127264_bb0115","first-page":"1","article-title":"Expanded recommendations for use of pneumococcal conjugate vaccines among adults aged \u226550 years: recommendations of the advisory committee on immunization practices \u2014 United States, 2024","volume":"74","author":"Kobayashi","year":"2025","journal-title":"MMWR"},{"key":"10.1016\/j.vaccine.2025.127264_bb0120","series-title":"Cost-effectiveness analysis of the use of V116, a 21-valent pneumococcal conjugate vaccine, in vaccine-naive adults aged \u2265 65 years in the United States","author":"Yi","year":"2024"},{"issue":"8","key":"10.1016\/j.vaccine.2025.127264_bb0125","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s11606-016-3651-0","article-title":"Incremental cost-effectiveness of 13-valent pneumococcal conjugate vaccine for adults age 50 years and older in the United States","volume":"31","author":"Stoecker","year":"2016","journal-title":"J Gen Intern Med"},{"issue":"10","key":"10.1016\/j.vaccine.2025.127264_bb0130","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.vaccine.2018.01.052","article-title":"The role of timeliness in the cost-effectiveness of older adult vaccination: a case study of pneumococcal conjugate vaccine in Australia","volume":"36","author":"Chen","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127264_bb0135","series-title":"CPI for all urban consumers (CPI-U): Medical care in U.S. city average, all urban consumers, not seasonally adjusted","author":"Bureau of Labor Statistics","year":"2023"},{"issue":"15","key":"10.1016\/j.vaccine.2025.127264_bb0140","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/jama.1996.03540150055031","article-title":"Recommendations of the panel on cost-effectiveness in health and medicine","volume":"276","author":"Weinstein","year":"1996","journal-title":"Jama-J American Medical Association"},{"key":"10.1016\/j.vaccine.2025.127264_bb0145","author":"United States Census Bureau"},{"key":"10.1016\/j.vaccine.2025.127264_bb0150","unstructured":"Hung Mei-Chuan, Srivastav Anup, Peng-Jun Lu, et al. Vaccination coverage among adults in the United States. National Health Interview Survey 2021. Immunization Services Division, National Center for Immunization and Respiratory Diseases, CDC; Leidos, Inc, Atlanta, GA. Available from: https:\/\/www.cdc.gov\/vaccines\/imz-managers\/coverage\/adultvaxview\/pubs-resources\/vaccination-coverage-adults-2021.html."},{"key":"10.1016\/j.vaccine.2025.127264_bb0155","unstructured":"Centers for Disease Control and Prevention, ABCs Bact Facts Interactive Data Dashboard | CDC Centers for disease control and prevention: Atlanta. GA 2024. Available at: https:\/\/www.cdc.gov\/abcs\/bact-facts\/data-dashboard.html."},{"key":"10.1016\/j.vaccine.2025.127264_bb0160","unstructured":"Stoecker C. Economic assessment of PCV20 for adults vaccinated with PCV13: presented at ACIP, October 19, 2022. Ctr Dis Control Prev 2022. Available from: https:\/\/stacks.cdc.gov\/view\/cdc\/122356."},{"issue":"25","key":"10.1016\/j.vaccine.2025.127264_bb0165","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1016\/j.vaccine.2019.04.087","article-title":"Pneumococcal epidemiology among us adults hospitalized for community-acquired pneumonia","volume":"37","author":"Isturiz","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127264_bb0170","doi-asserted-by":"crossref","unstructured":"Self W.H., Johnson K.D., Resser J.J., Whitney C.G., Baughman A, Kio M, Grijalva C.G., Traenkner J, Johnson J, Miller K.F., Rostad C.A., Yildirim I, Salazar L, Tanios R, Swan S.A., Zhu Y, Han J.H., Weiss T, Roberts C, Rouphael N; PNEUMO Study Investigators. Prevalence, Clinical Severity, and Serotype Distribution of Pneumococcal Pneumonia Among Adults Hospitalized With Community-Acquired Pneumonia in Tennessee and Georgia, 2018-2022. Clin Infect Dis. 2024 Oct 15;79(4):838-847. doi: 10.1093\/cid\/ciae316. PMID: 39016606; PMCID: PMC11478805.","DOI":"10.1093\/cid\/ciae316"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127264_bb0180","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.amepre.2006.03.008","article-title":"Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older","volume":"31","author":"Maciosek","year":"2006","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.vaccine.2025.127264_bb0185","unstructured":"Stoecker C. Economic assessment of PCV15 & PCV20: presentation to the ACIP June 25, 2021. Ctr Dis Control Prev 2021. Available from: https:\/\/stacks.cdc.gov\/view\/cdc\/109109."},{"issue":"4","key":"10.1016\/j.vaccine.2025.127264_bb0190","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10935-015-0394-3","article-title":"Estimated human and economic burden of four major adult vaccine-preventable diseases in the United States, 2013","volume":"36","author":"McLaughlin","year":"2015","journal-title":"J Prim Prev"},{"issue":"48","key":"10.1016\/j.vaccine.2025.127264_bb0195","doi-asserted-by":"crossref","first-page":"7634","DOI":"10.1016\/j.vaccine.2010.09.049","article-title":"Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States","volume":"28","author":"Rubin","year":"2010","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2025.127264_bb0200","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1080\/13696998.2018.1542520","article-title":"Estimated annual and lifetime labor productivity in the United States, 2016: implications fro economic evaluations","volume":"22","author":"Grosse","year":"2019","journal-title":"J Med Econ"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127264_bb0205","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1183\/13993003.00325-2015","article-title":"Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands","volume":"46","author":"Mangen","year":"2015","journal-title":"Eur Respir J"},{"issue":"12","key":"10.1016\/j.vaccine.2025.127264_bb0210","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa1408544","article-title":"Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults","volume":"372","author":"Bonten","year":"2015","journal-title":"N Engl J Med"},{"issue":"50","key":"10.1016\/j.vaccine.2025.127264_bb0215","doi-asserted-by":"crossref","first-page":"6011","DOI":"10.1016\/j.vaccine.2013.10.024","article-title":"Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions","volume":"31","author":"Cho","year":"2013","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2025.127264_bb0235","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/j.vaccine.2018.01.049","article-title":"Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults","volume":"36","author":"Suaya","year":"2018","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2025.127264_bb0245","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa1408544","article-title":"Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults","volume":"372","author":"Bonten","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.127264_bb0250","year":"2024","journal-title":"Pneumococcal Vaccine Recommendations"},{"issue":"9","key":"10.1016\/j.vaccine.2025.127264_bb0255","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.3201\/eid2209.150680","article-title":"Trends in pneumonia mortality rates and hospitalizations by organism, United States, 2002-2011(1)","volume":"22","author":"Wuerth","year":"2016","journal-title":"Emerg Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127264_bb0265","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1542\/peds.2012-3350","article-title":"Cost-effectiveness of using 2 vs 3 primary doses of 13-valent pneumococcal conjugate vaccine","volume":"132","author":"Stoecker","year":"2013","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2025.127264_bb0275","series-title":"Summary of three economic analyses on the use of PCVs among 50-64 year old adults in the United States. in Advisory Committee on Immunization","author":"Leidner","year":"2024"},{"key":"10.1016\/j.vaccine.2025.127264_bb0280","series-title":"Summary of three economic analyses on the use of 21-valent pneumococcal conjugate vaccine (PCV21) among adults in the United States. in Advisory Committee on Immunization","author":"Leidner","year":"2024"},{"key":"10.1016\/j.vaccine.2025.127264_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2024.02.021","article-title":"Pneumococcal vaccination strategies in 50-year-olds to decrease racial disparities: a US societal perspective cost-effectiveness analysis","author":"Altawalbeh","year":"2024","journal-title":"Value Health"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25005614?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25005614?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T15:01:26Z","timestamp":1749567686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25005614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":47,"alternative-id":["S0264410X25005614"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127264","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Economic evaluation of PCV21 in PCV-na\u00efve adults aged 50\u201364\u00a0years in the United States","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127264","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Merck & Co., Inc., Rahway, NJ, USA and its affiliates Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"127264"}}